Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors

NCT01455532 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01455532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
April 30, 2014
Enrollment
59 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm malignant